3/7
08:12 am
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
2/27
12:15 pm
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $20.00 to $18.00. They now have a "buy" rating on the stock.
High
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $20.00 to $18.00. They now have a "buy" rating on the stock.
2/27
10:50 am
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target lowered by analysts at Stifel Nicolaus from $27.00 to $23.00. They now have a "buy" rating on the stock.
Medium
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target lowered by analysts at Stifel Nicolaus from $27.00 to $23.00. They now have a "buy" rating on the stock.
2/26
08:26 pm
rlay
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates [Yahoo! Finance]
High
Report
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates [Yahoo! Finance]
2/26
04:05 pm
rlay
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
High
Report
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
2/24
04:05 pm
rlay
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
Medium
Report
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
2/19
04:05 pm
rlay
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
Low
Report
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
1/14
08:02 am
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
1/10
01:47 pm
rlay
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics surges [Seeking Alpha]
Medium
Report
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics surges [Seeking Alpha]
1/7
04:05 pm
rlay
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
12/20
01:37 pm
rlay
Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade [Yahoo! Finance]
Medium
Report
Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade [Yahoo! Finance]